Metastatic Sertoli cell tumour in a dog treated with surgery, and metronomic cyclophosphamide and toceranib phosphate

Authors: Hawkes CIK, Thomson MJ, O'Connell K, Morgan EJ
Publication: Australian Veterinary Practitioner, Volume 52, Issue 1, pp 21-30, Mar 2022
Publisher: Australian Veterinary Association

Animal type: Dog
Subject Terms: Abdomen, Clinical examination, Oncology
Article class: Clinical Report

---

Abstract:

A 4-year-old cryptorchid male Swiss shepherd dog was presented to a referral hospital with acute onset of restlessness and abdominal discomfort. Abdominal ultrasonography revealed a 5.61-cm x 7.23-cm hypoechoic mid-abdominal mass, suspected to be a neoplastic abdominal left testis. The dog underwent a coeliotomy with orchiectomy and a histopathological diagnosis of a Sertoli cell tumour (SCT) was made. Post-operative monitoring and cytological interpretation revealed metastasis to the left lumbar aortic lymph node 96 days later. The dog was commenced on metronomic cyclophosphamide and toceranib phosphate. Six months later the dog underwent lymphadenectomy of the affected lymph node. Disease recurrence was reported three months post-lymphadenectomy. The dog displayed intermittent, progressive disease and developed thrombocytopenia 17 months after diagnosis of metastatic disease. Despite cessation of chemotherapy, he developed neutropenia, thrombocytopenia and nonregenerative anaemia, consistent with myelotoxicosis, and was euthanized 23 months after initial diagnosis.

The incidence of metastatic SCT is low in dogs, and there are currently no defined criteria for optimal treatment. This is the first report, to the authors’ knowledge, of a metastatic SCT treated with metronomic cyclophosphamide and toceranib phosphate in the palliative setting.

---